AMPH Amphastar Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1297184 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.1%
TTM net income YoY-11.3%
TTM EPS YoY-3.5%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR-9.9%
Margins
Gross margin46.8%
Operating margin18.7%
Net margin13.3%
FCF margin18.6%
EBITDA margin22.4%
Returns
ROE12.4%
ROA5.9%
ROIC (approx.)8.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets52.4%
Debt / equity0.75x
Current ratio3.32x
Interest coverage5.25x
Cash quality & payout
Operating cash flow / net income1.77x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $207.61M | $183.90M | $171.17M | $183.10M | $191.84M | $174.41M | $170.53M | $186.52M |
| Cost of revenue | $107.98M | $90.43M | $100.85M | $97.44M | $93.19M | $87.92M | $85.28M | $99.88M |
| Gross profit | $99.63M | $93.47M | $70.32M | $85.67M | $98.65M | $86.49M | $85.25M | $86.65M |
| R&D expense | $20.08M | $22.16M | $26.74M | $23.31M | $22.35M | $20.08M | $20.10M | $18.14M |
| SG&A expense | $16.84M | $18.24M | $18.03M | $16.47M | $39.47M | $13.99M | $16.00M | $12.94M |
| Operating income | $50.77M | $39.73M | $13.63M | $35.61M | $25.32M | $42.18M | $37.29M | $45.14M |
| Interest expense | $6.76M | $6.66M | $6.55M | $6.63M | $6.28M | $6.28M | $6.29M | $6.42M |
| Pretax income | $49.06M | $38.54M | $10.05M | $31.91M | $21.51M | $39.34M | $30.86M | $43.96M |
| Income tax | $11.30M | $8.20M | $3.63M | $7.49M | $4.16M | $8.30M | $5.58M | $6.00M |
| Net income | $37.76M | $30.35M | $6.42M | $24.43M | $17.35M | $31.03M | $25.29M | $37.96M |
| EBITDA | $66.36M | $54.04M | $21.71M | $24.90M | $39.45M | $56.80M | $44.66M | $44.26M |
| EPS (basic) | 0.89 | 0.69 | 0.14 | — | 0.38 | 0.66 | 0.53 | — |
| EPS (diluted) | 0.87 | 0.67 | 0.14 | — | 0.37 | 0.64 | 0.51 | — |
| Weighted avg. shares (diluted) | 43.38M | 44.23M | 46.46M | — | 47.68M | 48.13M | 49.89M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $204.59M | $223.61M | $170.94M | $170.18M | $216.50M | $187.92M | $183.02M | $151.84M |
| Short-term investments | $26.05M | $66.51M | $121.01M | $112.64M | $59.94M | $44.06M | $54.10M | $70.04M |
| Receivables | $182.22M | $144.86M | $147.85M | $143.56M | $146.81M | $132.98M | $144.64M | $136.29M |
| Inventory | $173.92M | $179.91M | $170.19M | $176.89M | $185.93M | $191.73M | $185.48M | $153.74M |
| Current assets | $602.68M | $630.95M | $633.68M | $636.02M | $639.47M | $580.83M | $587.96M | $534.07M |
| PP&E, net | $312.87M | $316.06M | $307.23M | $310.57M | $308.69M | $310.24M | $307.60M | $297.35M |
| Goodwill | $3.30M | $3.31M | $3.33M | $3.40M | $3.40M | $3.40M | $3.16M | $3.05M |
| Intangibles | $607.90M | $615.30M | $527.07M | $533.34M | $539.61M | $545.88M | $552.15M | $558.39M |
| Total assets | $1.71B | $1.74B | $1.65B | $1.63B | $1.67B | $1.62B | $1.63B | $1.58B |
| Current liabilities | $181.43M | $263.20M | $164.48M | $158.16M | $205.23M | $176.41M | $199.05M | $173.76M |
| Short-term debt | $2.50M | $2.49M | $1.67M | $1.64M | $923,000 | $927,000 | $224,000 | $234,000 |
| Long-term debt | $610.50M | $609.56M | $609.80M | $608.75M | $608.58M | $607.73M | $603.86M | $601.63M |
| Total debt | $613.00M | $612.05M | $611.47M | $610.39M | $609.50M | $608.65M | $604.08M | $601.86M |
| Total liabilities | $897.17M | $975.61M | $874.77M | $840.49M | $889.48M | $857.85M | $874.99M | $845.17M |
| Shareholders' equity | $814.55M | $768.16M | $773.39M | $788.80M | $776.75M | $757.48M | $751.28M | $732.30M |
| Net debt | $408.41M | $388.44M | $440.53M | $440.21M | $393.00M | $420.73M | $421.06M | $450.02M |
| Shares outstanding | 42.65M | 42.53M | 44.64M | 45.65M | 46.35M | 46.49M | 47.67M | 47.62M |
| Cash flow statement | ||||||||
| Operating cash flow | $43.30M | $51.32M | $47.84M | $32.86M | $52.58M | $35.59M | $35.08M | $29.02M |
| Capital expenditure | $9.94M | $8.59M | $9.51M | $8.27M | $5.35M | $10.56M | $10.70M | $12.41M |
| Free cash flow | $33.36M | $42.73M | $38.33M | $24.59M | $47.23M | $25.03M | $24.38M | $16.61M |
| Investing cash flow | -$63.96M | $44.87M | -$16.73M | -$60.57M | -$19.62M | -$625,000 | $10.48M | -$35.68M |
| Financing cash flow | $1.71M | -$43.53M | -$30.21M | -$18.37M | -$4.35M | -$30.20M | -$14.50M | -$33.84M |
| Depreciation & amortization | $15.58M | $14.31M | $8.08M | -$10.71M | $14.13M | $14.62M | $7.37M | -$882,000 |
| Stock-based compensation | $7.01M | $7.09M | $9.27M | $6.21M | $6.30M | $6.38M | $8.39M | $5.63M |
| Share buybacks | $438,000 | $45.21M | $29.49M | $20.52M | $4.85M | $39.22M | $11.00M | $42.00M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.